TRDA — Entrada Therapeutics Cashflow Statement
0.000.00%
- $481.07m
- $153.65m
- $129.01m
- 61
- 63
- 79
- 76
Annual cashflow statement for Entrada Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -5.1 | -26.5 | -51.2 | -94.6 | -6.68 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | -5.98 | 0.345 | 2.6 | 10 | 7.33 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.174 | 0.282 | -3.42 | -11.1 | -3.66 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -10.8 | -25.6 | -50.9 | -93.8 | 140 |
Capital Expenditures | -0.63 | -2.33 | -4.58 | -2.89 | -5.61 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 0 | 0.007 | — | -146 | -133 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.63 | -2.32 | -4.58 | -149 | -138 |
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 0.038 | 50.1 | 307 | 0.479 | 21 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -11.4 | 22.2 | 252 | -242 | 22.4 |